I disagree with pretty much everything Danny has posted. Adam Furestein is a pawn of criminals and is under investigation. See: http://www.exposeadam.com/ thestreet.ocm stock price has gone from $32 to $1.77 - it is a front for criminals.
6 BSL4 labs and Army researchers do not sepnd millions investigating your drugs unless there is something there. Army researchers co-presented the ebola research with hemispherx - unheard of - but I'd be happy to be proven wrong and shown another co-presentation with a public sector company. The EU granted orphan drug status to Hemispherx for the treatment of ebola. I really don't think the EU authority is part of the hemispherx scam.
Hemispherx is currently the ONLY biotech doing research, the ONLY biotech that has an interest in CFS. Talk about cutting off your nose to spite your face. Again, please show me another company.
The amp511 protocol was changed in November of last year. You need the FDAs blessing to change a protocol. The protocol design now has 3 arms - 100 healthy volunteers, 100 untreated CFS patients and 100 treated CFS patients. What's that about?
Because they keep studying ampligen CFS patients, this puts them in the running for further studies under the "21st Century Cures Act". There is a reason that 30 CFS ampligen patients flew across country, during the holidays, in a snow storm to testify in front of the FDA Advisory committee. From all walks of life, including doctors -- to beg the FDA to approve ampligen. It does not work for everyone, but most on the advisory committee admitted that there is something there.
They are collecting NK cell data trying to find the group that responds to ampligen. They recently singed agreements with health care orgs in the EU, Turkey, Australia, New Zealand - to provide ampligen on a wider, named patient basis and to keep collecting more data. You'll find it curious, and you can read it in the 10-Q, that hemispherx ordered 750K worth of ampligen making material from their suppliers. They've upgraded their plant - mostly for Alferon, but Ampligen as well, to the tune of 15mil. They are holding an open house at the plant in about 10 days, for investors.
In my opinion, they are putting in place the infrastructure to treat a large sub-group of patients (I cannot think of any other reason for all the activity), in these countries and including the U.S. The audit for the manufacturing cost of ampligen is also in preparation. They make no money on the drug, why would they audit cost now? Last audit was in 1998. I believe the amp511 will in the not too distant future, be obsolete.
Just to touch on a few points.
6 BSL4 labs and Army researchers do not sepnd millions investigating your drugs unless there is something there. Army researchers co-presented the ebola research with hemispherx - unheard of - but I'd be happy to be proven wrong and shown another co-presentation with a public sector company. The EU granted orphan drug status to Hemispherx for the treatment of ebola. I really don't think the EU authority is part of the hemispherx scam.
Hemispherx is currently the ONLY biotech doing research, the ONLY biotech that has an interest in CFS. Talk about cutting off your nose to spite your face. Again, please show me another company.
The amp511 protocol was changed in November of last year. You need the FDAs blessing to change a protocol. The protocol design now has 3 arms - 100 healthy volunteers, 100 untreated CFS patients and 100 treated CFS patients. What's that about?
Because they keep studying ampligen CFS patients, this puts them in the running for further studies under the "21st Century Cures Act". There is a reason that 30 CFS ampligen patients flew across country, during the holidays, in a snow storm to testify in front of the FDA Advisory committee. From all walks of life, including doctors -- to beg the FDA to approve ampligen. It does not work for everyone, but most on the advisory committee admitted that there is something there.
They are collecting NK cell data trying to find the group that responds to ampligen. They recently singed agreements with health care orgs in the EU, Turkey, Australia, New Zealand - to provide ampligen on a wider, named patient basis and to keep collecting more data. You'll find it curious, and you can read it in the 10-Q, that hemispherx ordered 750K worth of ampligen making material from their suppliers. They've upgraded their plant - mostly for Alferon, but Ampligen as well, to the tune of 15mil. They are holding an open house at the plant in about 10 days, for investors.
In my opinion, they are putting in place the infrastructure to treat a large sub-group of patients (I cannot think of any other reason for all the activity), in these countries and including the U.S. The audit for the manufacturing cost of ampligen is also in preparation. They make no money on the drug, why would they audit cost now? Last audit was in 1998. I believe the amp511 will in the not too distant future, be obsolete.
Just to touch on a few points.